September 18, 2020
A randomised, double-blind, active-controlled, multicentre, head-to-head study of biologic monotherapy in biologic-naïve patients with active PsA. Subjects were randomised to receive subcutaneous Cosentyx 300 mg (n=426) at baseline, Weeks 1, 2, 3 and 4 until Week 48, or adalimumab citrate-free 40 mg s.c. at baseline and then every 2 weeks until Week 50. Primary endpoint was ACR20 response rate at Week 52. PASI 90 at Week 52 was a key secondary endpoint.